In Vitro Diagnostics Quality Control Market overview:
In a recent research report by Market Research Community, the In Vitro Diagnostics Quality Control (LDT) Market is expected to surpass USD 2.27 Billion by the year 2028, from USD 1.60 Billion in 2021.
In vitro diagnostic quality control tests are employed to validate the dependability of the IVD testing method to verify the precision of test results and assess the influence of environmental conditions and the operator’s performance on test results.
The molecular diagnostics segment is expected to grab contributable market share in the year 2022. The factors supporting the growth of the market are the launch of advanced technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), which boosted the demand for the molecular diagnostics market.
In the regional segment, Asia Pacific is projected to be the potential segment in the in vitro diagnostics quality control market. The factors expanding the growth of the market are the rising number of product manufacturing companies in the region. Further, the existence of regulatory authorities such as the Pharmaceuticals and Medical Devices Evaluation Agency (PMDA), the Ministry of Agriculture and Fisheries and Food, and the Ministry of Health, Labor and Welfare (MHLW) is expected to support the growth of the regional market.
The market is projected to grow at a significant pace reaching a CAGR of approximately 5.1%, over the forecast period of 2022–2028, despite a considerable fall in Service Operator sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.
The study is consolidated into major segments and further into sub-segments, such as by Type (Clinical Biochemistry, Molecular Diagnostics, Immunology, Critical Care, Microbiology, Haematology, Others), By Application (Hospitals laboratories, Specialty Diagnostic Centers, Clinical Research organizations, Academic Institutes, Others), to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.
Lastly, the report includes a regional analysis and country analysis with the latest trends, along with the major key players including Siemens Healthcare GmbH F. HOFFMANN-LA ROCHE LTD., QIAGEN, Illumina, Inc., Eurofins Scientific, Biodesix, Adaptive Biotechnologies, Biotheranostics, Rosetta Genomics Ltd., Guardant Health
Contact:
